Valuation: Memphasys Limited

Market Cap 12.38M 8.71M 7.8M 7.18M 6.5M 12.15M 827M 85.57M 34.35M 435M 32.69M 31.99M 1.37B P/E 2025
-1.57x
P/E 2026 -3.94x
Enterprise Value 15.45M 10.87M 9.73M 8.95M 8.11M 15.16M 1.03B 107M 42.86M 543M 40.78M 39.92M 1.71B EV / Sales 2025
24,365,123x
EV / Sales 2026 35,157,730x
Free-Float
61.3%
Yield 2025 *
-
Yield 2026 -
1 day-11.11%
1 week-20.00%
1 month-20.00%
3 months-46.67%
6 months-20.00%
Current year-42.86%
1 week 0
Extreme 0.004
0
1 month 0
Extreme 0.004
0
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.003
0.01
3 years 0
Extreme 0.002999
0.01
5 years 0
Extreme 0.002999
0.12
10 years 0
Extreme 0.002999
0.16
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 30/06/2021
Corporate Secretary - 07/10/2025
Director TitleAgeSince
Director/Board Member - 06/06/2018
Director/Board Member - 19/10/2025
Chairman - 18/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/23 Buy

Director

1,400,000 0.1459%
02/01/23 Buy

Chief Executive Officer

392,500 0.0409%
24/01/22 Sell

Director

1,350,000 0.1704%
Change 5-day change 1-year change 3-year change Capi.($)
-11.11%-20.00%-.--%-71.42% 8.71M
-1.72%+3.44%+22.84%+56.71% 258B
-2.00%+0.75%+7.82%+20.94% 163B
-3.73%-4.48%-19.14%+64.75% 150B
-1.66%-8.12%-58.32%-17.99% 60.84B
-.--%+2.46%-11.69%-7.41% 53.31B
-2.57%+3.30%+11.59%+44.40% 53.03B
+0.84%-3.12%+7.47%+62.40% 50.67B
-3.47%+1.04%+19.48%+69.17% 49.3B
-3.61%+1.99%+32.36%+93.99% 45.46B
Average -2.90%-2.27%+1.24%+31.55% 88.4B
Weighted average by Cap. -2.10%+0.15%+4.03%+44.65%

Financials

2025 2026
Net sales 0.53 0.37 0.33 0.31 0.28 0.52 35.2 3.64 1.46 18.52 1.39 1.36 58.39 0.66 0.46 0.41 0.38 0.35 0.65 43.95 4.55 1.83 23.12 1.74 1.7 72.91
Net income -5.04M -3.55M -3.18M -2.92M -2.65M -4.95M -337M -34.83M -13.98M -177M -13.3M -13.02M -558M -4.1M -2.89M -2.59M -2.38M -2.15M -4.03M -274M -28.36M -11.39M -144M -10.83M -10.6M -455M
Net Debt 4.9M 3.45M 3.09M 2.84M 2.58M 4.81M 328M 33.89M 13.61M 172M 12.95M 12.67M 543M 3.07M 2.16M 1.93M 1.78M 1.61M 3.01M 205M 21.19M 8.51M 108M 8.09M 7.92M 340M
Projected Income Statement - Annual - Memphasys Limited
Logo Memphasys Limited
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Employees
24
Date Price Change Volume
30/10/26 A$0.004000 -11.11% 2,039,101
29/10/26 A$0.004500 -.--% 212,699
28/10/26 A$0.004500 +12.50% 137,500
27/10/26 A$0.004000 -20.00% 111,000
23/10/26 A$0.005000 -.--% 1,666